#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej

We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go… because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander. Understanding TNFi resistance is path to: predicting it knowing best what to do with it @RheumNow https://t.co/22Y6iinSbH

McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB

What drives residual pain improvement in #JAKi treated pts? Dunno but #Baricitinib and #Sarilimab showed better pain decrease vs placebo and #Adalimumab. #OP0052 showed both #Tofacitinib & Adalimumab reduced pain more than placebo in PsA & RA if in remission @RheumNow @eular_org

Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B

VIGIBASE registry RA 39000+ pts JAKi and 231000+ pts TNFi *No increase in MACEs with JAKi 1.4% vs. 0.9% *JAKi Increase in DVT RR 3.99 and PE RR 3.5 adjusted on age and sex @RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky

Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF